Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

被引：0
|
作者：
Usmani, Saad Zafar
Karlin, Lionel
Benboubker, Lotfi
Nahi, Hareth
San-Miguel, Jesus
Trancucci, Danielle
Qi, Keqin
Stephenson, Tara
Perales-Puchalt, Alfredo
Chastain, Katherine
Chari, Ajai
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Ctr Hosp Lyon Sud, Lyon, France
[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] Univ Navarra, Pamplona, Spain
[6] Janssen Res & Dev, Raritan, NJ USA
[7] Janssen Res & Dev, Titusville, NJ USA
[8] Janssen Res & Dev, Spring House, PA USA
[9] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Nefedova, Yulia
    Wileyto, E. Paul
    Sembhi, Harjeet
    Strakovsky, Inna
    Nguyen, Chau
    Taneja, Rimzim
    Bondesson, Eva
    Eriksson, Helena
    Tuvesson, Helen
    BLOOD, 2020, 136
  • [43] Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study
    Rodriguez-Otero, Paula
    Dholaria, Bhagirathbhai
    Askari, Elham
    Reece, Donna E.
    van de Donk, Niels W. C. J.
    Chari, Ajai
    Goldschmidt, Hartmut
    Krishnan, Amrita Y.
    Martin, Thomas
    Mateos, Maria-Victoria
    Giles, Daniel Morillo
    Rodriguez, Cesar
    Rosinol, Laura
    San-Miguel, Jesus F.
    Sureda, Anna
    Waesch, Ralph
    Weisel, Katja
    Verona, Raluca I.
    Lin, Shun Xin Wang
    Prior, Thomas J.
    Weiss, Brendan M.
    Wade, Mark
    Goldberg, Jenna D.
    Oriol, Albert
    Hari, Parameswaran
    BLOOD, 2021, 138
  • [44] Arsenic trioxide (Trisenox®) in patients with relapsed or refractory multiple myeloma (MM):: Final report of a phase II clinical study.
    Hussein, MA
    Mason, J
    Saleh, MN
    Rifkin, RM
    Ravandi, F
    BLOOD, 2002, 100 (11) : 393B - 393B
  • [45] MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Costa, Luciano J.
    Perrot, Aurore
    Pei, Lixia
    Rubin, Maria L.
    Lantz, Kristen
    Sun, Weili
    Jaffe, Mindy
    Kobos, Rachel
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma
    Cornell, Robert Frank
    Baz, Rachid
    Richter, Joshua R.
    Rossi, Adriana
    Vogl, Dan T.
    Chen, Christine
    Shustik, Chaim
    Alvarez, Mariano J.
    Shen, Yao
    Unger, T. J.
    Ben-Shahar, Osnat
    Wang, Hongwei
    Baloglu, Erkan
    Senapedis, William
    Ma, Xiwen
    Landesman, Yosef
    Bai, Xiang
    Bader, Justin
    Xu, Hongmei
    Marshall, Tracey
    Chang, Hua
    Walker, Christopher J.
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Hofmeister, Craig C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (02) : E54 - E58
  • [47] Clinical impact of time to the best response in relapsed/refractory multiple myeloma patients receiving carfilzomib
    Cho, Hee Jeong
    Moon, Joon Ho
    Kim, Ju-Hyung
    Baek, Dong Won
    Sohn, Sang-Kyun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S166 - S166
  • [48] Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group
    Ntanasis-Stathopoulos, Ioannis
    Katodrytou, Eirini
    Hatjiharissi, Evdoxia
    Spanoudakis, Emmanouil
    Douka, Vasiliki
    Fotiou, Despina
    Labropoulou, Vasiliki
    Dalampira, Dimitra
    Spiliopoulou, Vasiliki
    Papadopoulou, Theodosia
    Christoulas, Dimitrios
    Malandrakis, Panagiotis
    Bouchla, Anthi
    Pappa, Vasiliki
    Kastritis, Efstathios
    Terpos, Evangelos
    Dimopoulos, Meletios
    Gavriatopoulou, Maria
    BLOOD, 2024, 144 : 6988 - 6990
  • [49] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
    Suvannasankha, Attaya
    Bahlis, Nizar J.
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Rocafiguera, Albert Oriol
    Voorhees, Peter M.
    Alonso, Aranzazu Alonso
    Callander, Natalie Scott
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne C.
    Zhou, Xiangdong
    Gupta, Ira V.
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.
    Rosenbaum, Cara Ann
    Stephens, Leonor Ano
    Kukreti, Vishal
    Zonder, Jeffrey A.
    Cole, Craig
    Zimmerman, Todd M.
    Reece, Donna Ellen
    Berdeja, Jesus G.
    Severson, Erica
    Revethis, Andrea
    Wolfe, Brittany
    McDonnell, Kathryn
    Nam, Jennifer
    Griffith, Kent A.
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345